



## **AcuCort CEO to present at BIO Europe Spring in Paris and BioStock Live in Stockholm**

The BIO Europe Spring conference is Europe's largest springtime Biotech partnering event. In addition to partnering meetings, BIO Europe Spring in Paris, France offers an agenda of presenting companies, and AcuCort has been selected to present in the Biotech sessions on March 24-25th. The company will be presented by CEO Ann Gidner.

Furthermore, AcuCort is attending the BioStock Live investor event in Stockholm, Sweden, on February 13th. At the event, Ann Gidner will give a company presentation as well as participate in an interview. The event will be webcast live and the interview will be available on [www.acucort.com](http://www.acucort.com).

"We are rapidly moving towards market authorization and commercialization of ISICORT®. It is of great importance to take our partnering dialogues forward, and I am most happy to represent AcuCort in these important forums for networking and collaboration. Having participated at BIO Europe since twenty years, I know the strength of this gathering", says Ann Gidner, interim CEO at AcuCort.

### **For more information, please contact**

Ms Ann Gidner, interim CEO, AcuCort AB

Phone +46 723 151414

Email [ann.gidner@acucort.se](mailto:ann.gidner@acucort.se)

- To register for **BioStock** in Stockholm on Feb 13th: <https://bit.ly/37F11oV>
- To register for **BIO Europe Spring** in Paris on March 23-25<sup>th</sup>: <https://informaconnect.com/bioeurope-spring/>

### **About AcuCort AB (publ)**

AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Altogether, this strengthens the company's assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden.

### **About BIO-Europe Spring**

This European partnering conference brings together some 2,600 delegates to hold 15,000 one-to-one meetings on global licensing opportunities. The conference attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and mid-sized pharmaceutical companies, investors and industry experts.

### **About BioStock**

BioStock is a leading Nordic digital news and analytics service focusing on the life science sector. The BioStock Live event has invited investors participating, and is also live streamed and recorded, providing presentations and industry insights to a broad audience.